Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T16:16:18.022Z.
Calculation as of: 2026-10-06T16:16:18.022Z.
Quote observation: 2026-10-06T16:14:57.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: dc6ba70d6a7a815a92143918ed9b9c2f02635c4477fd12c4733392629ce909df
PEG RATIO
N/A
Cardiff Oncology, Inc.
Market Cap
$84.40M
PEG Ratio
N/A
| NAME | MARKET CAP | PEG RATIO |
|---|---|---|
| Cardiff Oncology, Inc. (CRDF) | $84.40M | N/A |
| Humacyte, Inc. (HUMA)vs › | $84.37M | N/A |
| ProMIS Neurosciences, Inc. (PMN)vs › | $84.52M | N/A |
| Cognition Therapeutics, Inc. (CGTX)vs › | $84.98M | N/A |
| Citius Oncology, Inc. (CTOR)vs › | $83.67M | N/A |
| Atara Biotherapeutics, Inc. (ATRA)vs › | $85.42M | N/A |
| LENSAR Inc (LNSR)vs › | $82.90M | N/A |
| MediciNova, Inc. (MNOV)vs › | $82.45M | N/A |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $82.82M | N/A |
| CareCloud, Inc. (CCLD)vs › | $86.69M | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
